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Sir,
Karagas et al (2001) reported modest elevations in risk of basal
cell carcinoma (BCC) and squamous cell carcinoma (SCC)
accompanying oral steroid use but not for use of inhaled steroids.
The absence of effect from inhalants was attributed to their limited
systemic effects of glucocorticoids. Another possible explanation,
however, is the presence of bias owing to the confounding effects
of asthma, a condition for which inhaled glucocorticoids are often
used.
Asthma and other atopic conditions such as eczema and hay
fever are often treated with corticosteroids and have been found by
some epidemiologic studies to be associated with a reduced risk of
many types of cancers, although these findings are not consistent l
(Vena et al, 1985; McWhorter, 1988; Mills et al, 1992; Kallen et al,
1993; Vesterinen et al, 1993). It has been postulated that the
hypersensitivity to allergens associated with these conditions
protects against cancer by providing superior recognition of, and
immune response to, tumour antigens (Volkers, 1999). Conse-
quently, if atopic conditions do confer protection from cancer, the
failure to adjust for atopic disease in the original analysis would
bias the estimated relative risks of both oral and inhaled
glucocorticoids towards the null.
A reanalysis of data pertaining to oral glucocorticoid use
presented in the paper by Karagas et al suggests the possibility of
such confounding. Table 1 provides the distribution among cases
and controls of oral glucocorticoid use (use for 1 month or longer)
subcategorised by reason for possible steroid use. The data for
steroid users were pooled into two groups: one group representing
subjects treating possibly atopic conditions (specifically, those
using steroids for ‘respiratory conditions and asthma’ and
‘allergy’) and the other group representing subjects with other
conditions (those categorised under other reasons).
Table 1 Distribution of oral glucocorticoid use and skin cancer (based on data presented in Table 1 of
Karagas et al, 2001)
Controls BCC SCC
Steroid use
a Reason N (%) N (%) N (%)
No 491 (88.8) 534 (85.9) 245 (81.9)
Yes Any 31 (5.6) 44 (7.1) 27 (9.0)
Treat possible atopic conditions
b 16 (2.9) 14 (2.3) 10 (3.3)
Treat possible non-atopic conditions
c 15 (2.7) 30 (4.8) 17 (5.7)
BCC¼basal cell carcinoma; SCC¼squamous cell carcinoma.
aUse of oral glucocorticoid use for 1 month or longer.
bIncludes ‘respiratory conditions and asthma’ and ‘allergies’.
cIncludes ‘musculoskeletal and connective tissue disease’,
‘neoplasm’, ‘gastrointestinal disease’, ‘other’.
Table 2 Association between oral glucocorticoid use to treat possible atopic/non-atopic conditions and
skin cancer risk
BCC SCC
Steroid use
a Reason OR (95% CI) OR (95% CI)
No — —
Yes Any 1.31 (0.81–2.10) 1.75 (1.02–2.99)
Treat possible atopic conditions
b 0.80 (0.39–1.67) 1.25 (0.56–2.80)
Treat possible non-atopic conditions
c 1.84 (0.98–3.46) 2.27 (1.12–4.62)
BCC¼basal cell carcinoma; SCC¼squamous cell carcinoma; OR¼odds ratio; CI¼confidence interval.
aUse of oral
glucocorticoid use for one month or longer.
bIncludes ‘respiratory conditions and asthma’ and ‘allergies’.
cIncludes
‘musculoskeletal and connective tissue disease’, neoplasm, gastrointestinal disease, other.
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were calculated to measure the association between risk of BCC
and SCC and oral steroid use (Table 2). Stronger increases in risk
of each skin cancer were found for steroid use to treat
(supposedly) non-atopic conditions, compared to nonusers.
Steroid use to possibly treat atopic conditions was not found to
be associated with either type of cancer. These findings suggest
that the effects of atopic conditions may confound the association
between glucocorticoids and skin cancer risk. The analysis is
limited in that the odds ratios have not been adjusted for other
confounding factors, although the adjusted odds ratios in the
original analysis were very similar in magnitude to the unadjusted
odds ratios. Another limitation involves the fact that four cases
(two BCC, two SCC) that received steroid treatment for conditions
in more than one category were not identified as such in the
original table, and so could not be adjusted for in this analysis.
However, other analyses involving different assumptions about the
possible joint conditions suggested that the findings would not be
greatly influenced by this problem. Both of these issues could be
addressed by the authors through reanalysis of the original study
data. It would also be interesting to know whether a similar
reanalysis of inhaled steroid use resulted in comparable findings.
REFERENCES
Kallen B, Gunnarskog J, Conradson TB (1993) Cancer risk in asthmatic subjects
selected from hospital discharge registry. E u rR e s p i rJ6(5): 694–697
Karagas MR, Cushing Jr GL, Greenberg ER, Mott LA, Spencer SK,
Nierenberg DW (2001) Non-melanoma skin cancers and glucocorticoid
therapy. Br J Cancer 85(5): 683–686
McWhorter WP (1988) Allergy and risk of cancer A prospective study using
NHANESI followup data. Cancer 62(2): 451–455
Mills PK, Beeson WL, Fraser GE, Phillips RL (1992) Allergy and cancer:
organ site-specific results from the Adventist Health Study. Am J
Epidemiol 136(3): 287–295
Vena JE, Bona JR, Byers TE, Middleton Jr E, Swanson MK, Graham S (1985)
Allergy-related diseases and cancer: an inverse association. Am J
Epidemiol 122(1): 66–74
Vesterinen E, Pukkala E, Timonen T, Aromaa A (1993) Cancer in-
cidence among 78,000 asthmatic patients. Int J Epidemiol 22(6):
976–982
Volkers N (1999) Wheezing, sneezing, and cancer risk–still an open door. J
Natl Cancer Inst 91(22): 1916–1918
Reply: Glucocorticoid use and skin cancers
MR Karagas*,1 and DW Nierenberg
1
1Departments of Community and Family Medicine, Medicine, Pharmacology and Toxicology, and the Norris Cotton Cancer Center, Dartmouth Medical
School, Lebanon, NH 03756, USA
British Journal of Cancer (2003) 89, 952–953. doi:10.1038/sj.bjc.6601222 www.bjcancer.com
& 2003 Cancer Research UK
                
Sir,
We appreciate Dr Purdue’s interest in our report on use of
glucocorticoids and skin cancers. As suggested in his letter, we
reclassified indication for steroid use into two categories: (1)
atopic conditions (i.e. ‘respiratory conditions and asthma’ and
‘allergies’) and (2) non-atopic conditions (i.e. ‘musculoskeletal and
connective tissue disease’, ‘neoplasm’, ‘gastrointestinal disease’,
and ‘other condition’) (Table 1). In the reanalysis of the data, we
noted an error in Table 1 of the original report. There were only
two controls that used glucocorticoids for allergies (the seven
controls in the original report included users of inhaled steroids).
The correct numbers appear in Table 1 below and are restricted to
oral users. The odds ratios associated with oral glucocorticoid use,
stratified by Dr Purdue’s classification, are shown in Tables 2
and 3. The results for ‘any use’ differ very slightly from the original
report because we removed individuals with more than one
indication or with missing data on the indication for use for this
reanalysis.
Table 1 Oral glucocorticoid use according to indication among skin
cancer cases and controls
Steroid
use
a Indication
Controls
N (%)
BCC
N (%)
SCC
N (%)
No 491 (95.0) 534 (93.0) 245 (91.1)
Yes Any use
b 26 (5.0) 40 (7.0) 24 (8.9)
Treat possible
atopic conditions
c
11 (2.1) 12 (2.1) 9 (3.4)
Treat possible
non-atopic conditions
d
15 (2.9) 28 (4.9) 15 (5.6)
BCC¼basal cell carcinoma; SCC¼squamous cell carcinoma.
aUse of oral
glucocorticoid use for 1 month or longer.
bExcludes three individuals with more
than one indication (two BCC, one SCC) and two individuals with missing data on
indication for use (one BCC, one SCC).
cIncludes ‘respiratory conditions and asthma’
and ‘allergies’.
dIncludes ‘musculoskeletal and connective tissue disease’, ‘neoplasm’,
‘gastrointestinal disease’, ‘other condition’.
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